Triple negative breast cancer

Common Name(s)

Triple negative breast cancer

Triple negative breast cancer (TNBC) describes any type of breast cancer that lacks three types of receptors that are often used for targeted treatments. These three types of receptors are estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/neu). These receptors are involved in cell signaling and are found on affected cells in breast cancer that is not TNBC. There are different forms of TNBC, and about 10-20 percent of women who are diagnosed with breast cancer have a TNBC form.

Women who are younger in age, African American or Hispanic, and/or have mutations in the BRCA1 gene are more likely to have TNBC. TNBC often spreads more quickly than other types of breast cancer and presents a higher risk of coming back or recurring, especially in the first few years after treatment. After the first 3-5 years following treatment, the risk of recurrence of TNBC matches that of non-TNBC.

TNBC is diagnosed by taking a biopsy, or tissue sample, of the cancer. TNBC is less likely to respond to hormonal treatments but often does respond well to chemotherapy, radiation therapy, and surgery. If you have been diagnosed with TNBC, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members. Support groups are a good source of information and can connect you with others who have been affected by breast cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple negative breast cancer" returned 915 free, full-text research articles on human participants. First 3 results:

Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
 

Author(s): Steven R Hall, Jay Toulany, Leah G Bennett, Camilo F Martinez-Farina, Andrew W Robertson, David L Jakeman, Kerry B Goralski

Journal: J. Pharmacol. Exp. Ther.. 2017 Nov;363(2):196-210.

 

Jadomycins are natural products that kill drug-sensitive and multidrug-resistant (MDR) breast cancer cells. To date, the cytotoxic activity of jadomycins has never been tested in MDR breast cancer cells that are also triple negative. Additionally, there is only a rudimentary understanding ...

Last Updated: 14 Sep 2017

Go To URL
Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
 

Author(s): Cecília P Popolin, João P B Reis, Amanda B Becceneri, Angélica E Graminha, Márcio A P Almeida, Rodrigo S Corrêa, Legna A Colina-Vegas, Javier Ellena, Alzir A Batista, Márcia R Cominetti

Journal:

 

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype. The high rate of metastasis associated to the fact that these cells frequently display multidrug resistance, make the treatment of metastatic disease difficult. Development of antitumor metal-based ...

Last Updated: 12 Sep 2017

Go To URL
Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.
 

Author(s): Shuping Yin, Vino T Cheryan, Liping Xu, Arun K Rishi, Kaladhar B Reddy

Journal:

 

Women with triple negative breast cancer (TNBC) have poor prognosis compared to other breast cancer subtypes. There were several reports indicating racial disparity in breast cancer outcomes between African American (AA) and European American (EA) women. For example, the mortality ...

Last Updated: 17 Aug 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple negative breast cancer" returned 62 free, full-text review articles on human participants. First 3 results:

MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis.
 

Author(s): Lingshuang Lü, Xuhua Mao, Peiyi Shi, Biyu He, Kun Xu, Simin Zhang, Jianming Wang

Journal: Medicine (Baltimore). 2017 Jun;96(22):e7085.

 

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by their aggressive nature and poor associated survival. MicroRNAs (miRs) have been found to play an important role in the occurrence and development of human cancers, but their role in the prognosis ...

Last Updated: 31 May 2017

Go To URL
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.
 

Author(s): Alberto Ocana, Atanasio Pandiella

Journal: Oncotarget. 2017 Mar;8(13):22218-22234.

 

Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this ...

Last Updated: 21 Jan 2017

Go To URL
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
 

Author(s): Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni

Journal: Nat Rev Clin Oncol. 2016 Nov;13(11):674-690.

 

Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of targeted therapies and the poor prognosis of patients with TNBC have fostered a major effort to discover ...

Last Updated: 27 Sep 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
 

Status: Available

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 6 Oct 2010

Go to URL
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 19 Jul 2017

Go to URL
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 22 May 2017

Go to URL